Data Monitoring Committee (DMC) has performed another, scheduled review of the CHF trial data and recommended continuation of the trial without modification. Enrollment of this Phase 3 trial is expected to be completed by the end of 2018.
LVAD National Institutes for Health (NIH) Phase 2 trial has also completed enrollment with 12-month data read-out expected in the next quarter (Q3 CY18). Mesoblast is actively pursuing a potential accelerated entry pathway for MPC-150-IM into the cardiovascular market that may be provided by RMAT designation.
So, my take on this is both of these Tier 1 trials are confirmed on track with results coming in expected time-frames.
- Forums
- ASX - By Stock
- MSB
- Ann: MSB Clinical Program Update For MPC-150-IM In Heart Failure
Ann: MSB Clinical Program Update For MPC-150-IM In Heart Failure, page-2
-
- There are more pages in this discussion • 115 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B |
Open | High | Low | Value | Volume |
$1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 94863 | $1.13 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.13 | 5000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 85863 | 1.125 |
3 | 60500 | 1.120 |
3 | 49858 | 1.115 |
10 | 234700 | 1.110 |
3 | 20500 | 1.105 |
Price($) | Vol. | No. |
---|---|---|
1.130 | 1000 | 1 |
1.135 | 15000 | 2 |
1.140 | 10000 | 1 |
1.150 | 27892 | 3 |
1.155 | 25000 | 1 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |